Senti Bio reports Q1 net loss $18.7M; cash $76.1M; SENTI-202 IND on track for 2H 2023

Senti Biosciences, Inc.

2023-Q1 EPS reported -$0.42 revenue$1,286,000

Net loss of $18.7M ($0.42 per share) vs $11.8M loss in Q1 2022; revenue $1.3M.
Cash, equivalents & short-term investments $76.1M; cash runway expected through at least Q1 2024.
R&D expense $11.3M (+49% YoY) from increased headcount for preclinical programs.
SENTI-202 logic-gated CAR-NK on track for IND filing in 2H 2023; new AACR data shown.
Technology transfer to Alameda cGMP facility started to support clinical-scale manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Senti Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $18.7 million, EPS $0.42 per basic and diluted share.

Period: the quarter ended March 31, 2023
Net income: $18.7 million
EPS: $0.42 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.